Publications by authors named "P Rojo"
Article Synopsis
- Chiral nitrogen-containing compounds are essential in various industries, but their synthesis can be challenging due to a vast range of chemical possibilities.
- This research details a selective method to create 3,3-diarylallyl phthalimides, which, when treated with iridium catalysts, transform into 3,3-diarylpropyl amines with very high enantioselectivity (98-99% ee).
- The study highlights the role of alkene purity in achieving high enantioselectivity and illustrates how the resulting chiral propylamines can be used to make important bioactive drugs like tolterodine and tolpropamine.
Penta Network: State-of-the-Art Research in Pediatric Human Immunodeficiency Virus.
Clin Perinatol
December 2024
The Penta Network has made significant strides in pediatric human immunodeficiency virus (HIV) research, initially focusing on clinical trials for children in Europe, before expanding globally to countries with high HIV prevalence. Key contributions include the ODYSSEY trial, which established dolutegravir as a superior treatment for children and the Early-treated Perinatally HIV-infected Individuals: Improving Children's Actual Life with Novel Immunotherapeutic Strategies consortium, aimed at developing strategies for HIV remission. The ongoing empirical and thrive projects address advanced HIV disease, particularly severe pneumonia and postdischarge mortality in children.
View Article and Find Full Text PDFIn this work our aim was to identify early biomarkers in plasma samples associated with mortality in children with perinatal HIV treated early in life, to potentially inform early intervention targeting this vulnerable group. 20/215 children (9.3%) with perinatal HIV, enrolled within 3 months of age died prematurely within the first year of the study, despite early ART initiation.
View Article and Find Full Text PDFArticle Synopsis
- The study examined outcomes for infants with perinatally-acquired HIV who started early ART in South Africa, Mozambique, and Mali, focusing on mortality, viral suppression, and engagement in care over three years.
- Out of 215 infants monitored, the 1-year death probability was 10%, which rose to 12% by the second and third years, with high baseline viral load identified as a significant risk factor for mortality.
- Of the children, only 42% maintained sustained viral control for a year, with adherence to ART deemed optimal in 81% of visits, although lower adherence was linked to female sex at birth, younger diagnosis age, and adverse maternal social circumstances.
Article Synopsis
- The study aimed to evaluate hearing outcomes at 24 months for infants with mild congenital cytomegalovirus (cCMV) infection, comparing those who received antiviral treatment to those who did not.
- Utilizing data from the European Registry of Children with cCMV, researchers included infants diagnosed with cCMV early in life, who had normal physical exams and mild imaging findings.
- Results showed that 34.7% of the 196 participants received antiviral treatment, but there was no significant difference in hearing loss prevalence between treated (4.6%) and untreated groups (6.3%) after two years.